Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.8412.7000
Address
60-66 Hanover Street Fitzroy, Victoria (VIC) 3065
Description
Genetic Technologies Ltd. engages in the provision of molecular risk assessment tests for cancer. It operates through ,the EasyDNA, AffinityDNA, and GeneType/Corporate segments. The EasyDNA segment focuses on EasyDNA branded test sales and expenses. The AffinityDNA segment deals with AffinityDNA branded test sales and expenses. The GeneType/Corporate segment includes the GeneType branded test sales and expenses, including corporate charges. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.04 - 0.3
Trade Value (12mth)
AU$2,140.00
1 week
-12%
1 month
-42.86%
YTD
-66.15%
1 year
-78%
All time high
81.20
EPS 3 yr Growth
7633.300%
EBITDA Margin
-127.70%
Operating Cashflow
-$10m
Free Cash Flow Return
-67.60%
ROIC
-83.30%
Interest Coverage
-375.70
Quick Ratio
3.10
Shares on Issue (Fully Dilluted)
115m
HALO Sector
Industrials
Next Company Report Date
29-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
19 July 24 |
Change in substantial holding
×
Change in substantial holding |
18 July 24 |
Change in substantial holding
×
Change in substantial holding |
16 July 24 |
Appointment of CFO and Company Secretary
×
Appointment of CFO and Company Secretary |
16 July 24 |
Application for quotation of securities - GTG
×
Application for quotation of securities - GTG |
16 July 24 |
S708A Cleansing Notice
×
S708A Cleansing Notice |
12 July 24 |
Change in substantial holding
×
Change in substantial holding |
09 July 24 |
GeneType to Enter Canadian and New Zealand Markets
×
GeneType to Enter Canadian and New Zealand Markets |
28 June 24 |
Business Update - June 2024
×
Business Update - June 2024 |
28 June 24 |
Resignation of CFO and Company Secretary
×
Resignation of CFO and Company Secretary |
25 June 24 |
GeneType identifies 79.5% at risk of serious disease
×
GeneType identifies 79.5% at risk of serious disease |
24 June 24 |
Change in substantial holding
×
Change in substantial holding |
21 June 24 |
GTG Live Investor Webinar and Q&A - June 27
×
GTG Live Investor Webinar and Q&A - June 27 |
18 June 24 |
GTG Expands Operational Capacity in North America
×
GTG Expands Operational Capacity in North America |
12 June 24 |
Notification regarding unquoted securities - GTG
×
Notification regarding unquoted securities - GTG |
05 June 24 |
Change in substantial holding
×
Change in substantial holding |
05 June 24 |
GeneType and Stayhealthy Announce Landmark Distribution Agre
×
GeneType and Stayhealthy Announce Landmark Distribution Agre |
29 May 24 |
Launch of test for 100% risk of breast and ovarian cancer
×
Launch of test for 100% risk of breast and ovarian cancer |
20 May 24 |
Form F-1 Registration Statement
×
Form F-1 Registration Statement |
06 May 24 |
GTG and Wellworks for You sign B2B sales and marketing deal
×
GTG and Wellworks for You sign B2B sales and marketing deal |
30 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
24 April 24 |
Change in substantial holding
×
Change in substantial holding |
23 April 24 |
GTG announces closing of US$2M Registered Direct Offering
×
GTG announces closing of US$2M Registered Direct Offering |
23 April 24 |
Prospectus Supplement
×
Prospectus Supplement |
23 April 24 |
Notification regarding unquoted securities - GTG
×
Notification regarding unquoted securities - GTG |
22 April 24 |
Proposed issue of securities - GTG
×
Proposed issue of securities - GTG |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.